目的：分析喉罩在肥胖患者眼科日间手术中的应用特点。方法：选择 2021 年 1 月— 2024 年 3 月在中山大学中山眼科中心行日间眼科手术 且体质量指数（body mass index，BMI）≥25 kg/m²的男性患者进行分析，将患者分为2组：超重组（BMI 25~<30 kg/m2）及肥胖组（BMI≥30 kg/m²）。比较两组患者入室时（T₁）、诱导后（T₂）、喉罩置入后（T₃）、手术开始时（T₄）、手术开始10 min（T₅）、手术结束时（T₆）、入麻醉恢复室（post-anesthesia care unit，PACU）（T₇）、喉罩拔除时（T₈）的血流动力学和血氧饱和度变化情况；并分析喉罩置入后（T₃）、手术开始时（T₄）、手术开始10 min（T₅）、手术结束时（T₆）和喉罩拔除时（T₈）患者的呼吸参数变化情况，记录两组患者的喉罩通气成功率及复苏室的停留时间。结果：纳入 118 例患者，其中超重组 57 例、肥胖组 61 例。两组均未出现喉罩通气失败病例，肥胖组在T₃、T₄、T₅、T₆以及T₈等时点气道峰压均高于超重组（P < 0.05）；肥胖组的呼吸道不良事件发生率高于超重组（P < 0.05）。两组患者围术期生命体征平稳（P > 0.05），复苏室停留时间在组间比较差异无统计学意义（P > 0.05）且均顺利日间手术离院。结论：喉罩通气下全身麻醉能安全应用在肥胖患者眼科日间手术中，高BMI与高气道峰压相关。

Objective: General anesthesia using laryngeal mask airway (LMA) ventilation can facilitate ambulatory ophthalmic surgery, however, there remains debates about the use of LMA for obese patients. This study retrospectively analyzed the application of LMA in obese patients for ambulatory ophthalmic surgery. Methods: In this retrospective study, we analyzed all patients with a BMI≥25 kg/m2 who underwent ambulatory ophthalmic surgery under general anesthesia at the Zhongshan Ophthalmic Center of Sun Yat-sen University from January 2021 to March 2024.  The patients were divided into two groups: overweight group (BMI 25~<30 kg/m2) and obese group (BMI ≥30 kg/m2) . We compared the changes in hemodynamics and oxygen saturation at the several time points, baseline after entering operating room (T₁), anesthesia induction (T₂), LMA insertion (T₃), start of surgery (T₄), 10 minutes after surgery (T₅), surgery completion (T₆), transfer to PACU (T₇), and LMA removal (T₈);and analyzed the changes in respiratory parameters of the patient at T₃, T₄, T₅, T₆, and T₈ time points between both groups. We also observed the differences in success rate of LMA insertion and ventilation and PACU stay time as well as time to discharge home between two groups. Results: 118 cases were found suitable for the final analysis and divided into overweight group (n=57) and obese group (n=61). All patients in the two groups uneventfully completed the ophthalmic ambulatory surgery and discharged home under the laryngeal mask airway ventilation, none of patients in both group displayed LMA ventilation failure. The hemodynamics and oxygen saturation in both groups were stable during perioperative period(P > 0.05). The peak airway pressures in obese group were dramatically increased than in overweight group at T₃, T₄, T₅, T₆ and T8 time points (P < 0.05), and the incidences of adverse respiratory events in obese group were significant higher than in overweight group （P < 0.05）. The PACU stay time was comparable in both groups (P > 0.05). Conclusion: LMA can be safely used for obese patients undergoing ophthalmic surgery, high BMI is related to high peak airway pressures.

目的：调查抗VEGF药物治疗湿性年龄相关性黄斑变性(wet age-related macular degeneration, wAMD)5年的疗效。方法：2011年至2021年于北京医院眼科诊断为wAMD的患者共84人103只眼进行回顾性分析。抗VEGF治疗采用3+PRN方案。观察5年来的最佳矫正视力(best-corrected visual acuity，BCVA)、玻璃体腔注射次数、随访次数和病灶的解剖学变化。结果：治疗5年后平均BCVA为38.1个字母，与基线相比下降9.4个字母，差异有统计学意义(P<0.001)。23.3%的患眼5年后可维持初始视力。5年内平均注射次数为13.8次，第1年注射次数最多，平均为4.3次。5年内平均随访次数为24.3次，仅有34.0%的患眼可遵循每次随访间隔≤3个月。5年后有68.0%的患眼出现纤维瘢痕，27.2%的患眼出现地图样萎缩，69.0%(71/103)的患眼存在持续的色素上皮脱离(pigment epithelial detachment，PED)。年龄、基线BCVA、是否初始治疗、随访年限、注射次数、中心视网膜厚度 (central retina thickness，CRT)、地图样萎缩等对BCVA有显著影响。结论：多数患者在抗VEGF治疗1年内可维持视力，但5年以上维持效果不佳。早期诊治、提高注射频率，可能是未来改善预后的研究方向。

Objective:To investigate the efficacy of anti-VEGF injection in the treatment of wet age-related macular degeneration (wAMD) for 5 years. Methods: A total of 84 patients (103 eyes) wAMD diagnosed in Department of Ophthalmology in Beijing Hospital from 2011 to 2021 were analyzed retrospectively. 3 + PRN regimen was applied for anti-VEGF treatment. The changes of best corrected visual acuity (BCVA), the number of intravitreal injections and the number of follow-up visits, and the anatomical changes of the lesions in the past 5 years were collected. Results: The average BCVA after 5 years was 38.1 letters, indicating a decrease of 9.4 letters comparing to baseline, which was statistically significant (P<0.001). 23.3% of the eyes could maintain the baseline BCVA after 5 years. The average injection times within 5 years was 13.8, and the injection was concentrated in the first year, with an average of 4.3. The average number of follow-up visits within 5 years was 24.3, and only 34.0% of the affected eyes could keep the follow-up interval ≤3 months. After 5 years, 68.0% of the eyes developed fibrous scar, 27.2% developed geographic atrophy, and 69.0% (71/103) had consistent pigment epithelial detachment. Factors significantly affect BCVA include: age, baseline BCVA, initial treatment, follow-up time, injection times, central retinal thickness, geographic atrophy and so on. Conclusion: Most patients can maintain vision within the first year after anti-VEGF treatment, but the efficacy is poor for more than 5 years. Early diagnosis and treatment, and increased injection frequency may be the research direction for improving prognosis in the future.